Embecta Corporation
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Embecta Corporation
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
/ 
Frequently asked questions
To buy Embecta Corporation stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Embecta Corporation by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Embecta Corporation is EMBC:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Embecta Corporation has its primary listing on NASDAQ. You can trade Embecta Corporation with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Embecta Corporation is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Embecta Corporation as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Embecta Corporation.